Related Experiment Video

Updated: May 23, 2026

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
10:49

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

Tyrosine kinase inhibitors in acute and chronic leukemias

Maro Ohanian1, Jorge Cortes, Hagop Kantarjian

  • 1The University of Texas, M. D. Anderson Cancer Center, Department of Leukemia, 1515 Holcombe Blvd, Box 428, Houston, TX 77030, USA.

Expert Opinion on Pharmacotherapy
|April 24, 2012
PubMed
Abstract

Insights

Newer tyrosine kinase inhibitors (TKIs) offer improved treatment options for chronic myelogenous leukemia (CML) and Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL). Research continues for advanced TKIs, including those targeting BCR-ABL and FLT-3 mutations in leukemia.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • Significant advancements have been made in understanding BCR-ABL tyrosine kinase inhibitor (TKI) resistance mechanisms since imatinib's approval.
  • Targeted TKI therapy remains a critical area of research and development for acute and chronic leukemia treatment.

Purpose of the Study:

  • To review current and investigational TKI treatments for chronic myelogenous leukemia (CML), Philadelphia-chromosome positive acute lymphoblastic leukemia (Ph+ ALL), and acute myelogenous leukemia (AML).

Main Methods:

  • Literature review of approved and investigational tyrosine kinase inhibitors.
  • Analysis of treatment strategies for CML, Ph+ ALL, and AML.
  • Evaluation of TKI efficacy against specific mutations, including T315I and FLT-3 internal tandem duplications.

Main Results:

  • More potent BCR-ABL TKIs are now available, expanding front-line and second-line treatment options for CML and Ph+ ALL.
  • Ponatinib shows promise in overcoming T315I mutations in resistant CML and Ph+ ALL.
  • FLT-3 inhibition is a key area of study for AML patients with FLT-3 internal tandem duplication mutations.

Conclusions:

  • The selection between nilotinib and dasatinib should be individualized based on side effects, drug interactions, comorbidities, and mutational status.
  • Ponatinib represents a significant advancement for managing T315I-mutated leukemias.
  • Ongoing research into FLT-3 inhibitors holds potential for AML treatment.

More Related Videos

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Receptor Tyrosine Kinases01:26

Receptor Tyrosine Kinases

Receptor tyrosine kinases or RTKs are membrane-bound receptors that phosphorylate specific tyrosine on protein substrates. RTKs regulate cellular growth, differentiation, survival, and migration. They contain an extracellular ligand binding domain, a transmembrane domain, and a cytosolic tail with intrinsic kinase activity. Several extracellular signaling molecules activate RTKs in one or more ways and relay the signal downstream. Ligands such as platelet-derived growth factor (PDGF) or...
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers01:26

Treatment for Pulmonary Arterial Hypertension: Receptor Tyrosine Kinase Inhibitors and Calcium Channel Blockers

Receptor tyrosine kinase inhibitors (TKIs) and calcium channel blockers (CCBs) are two critical categories of drugs employed in the treatment of pulmonary artery hypertension (PAH). PAH is a disease that causes high blood pressure in the pulmonary arteries, resulting in chest pain, fatigue, and shortness of breath.
TKIs, such as imatinib (Gleevec), are particularly effective in tackling the growth and mitogenic factors that become upregulated in PAH patients. These factors contribute to the...
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...